A recent study from the Department of Genome Sciences, University of Washington, Seattle, USA shows that “Extension of murine life span by overexpression of catalase targeted to mitochondria.” This study was published in the 24 June 2015 issue of the journal “Science” [the number 2 journal in General Science with an I.F of 31.477] by Prof Rabinovitch PS, Schriner and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small Molecule-based Life extension therapy: AICAR, an analog of AMP, increases catalase expression, decreases oxidative damage and promotes longevity via up regulation of its target gene
This study suggests, for the first time, that AICAR, by increasing the expression of its target genes, it may decrease: (1) Cardiac pathology and cataract development; (2) oxidative damage; (3) H2O2 production; (4) and the development of mitochondrial deletions. Thus, pharmacological formulations encompassing “AICAR or its analogues“ may be used to decrease oxidative damage and increase the lifespan of an individual.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Small Molecule-based Life extension therapy: AICAR, an analog of AMP, increases catalase expression, decreases oxidative damage and promotes longevity via up regulation of its target gene, 22/May/2015, 12.17 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org
* Research cooperation
Undisclosed information: How AICAR increases catalase expression